The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.
about
Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Medicinal properties of Hericium erinaceus and its potential to formulate novel mushroom-based pharmaceuticalsFuture perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of MelanomaInhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment.STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing CancersHigh EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion.Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant MelanomaCancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape?Overcoming tumor-mediated immunosuppression.The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.Upregulation of thioredoxin-1 in activated human NK cells confers increased tolerance to oxidative stress.Opportunities and challenges for TCR mimic antibodies in cancer therapyGene expression study and pathway analysis of histological subtypes of intestinal metaplasia that progress to gastric cancer.The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.Cell Signaling Pathways That Regulate Antigen PresentationBiological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.Inhibition of MHC-I by Brucella abortus is an early event during infection and involves EGFR pathway.Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer.Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells.Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility.Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future OptionsDrug resistance and new therapies in colorectal cancer
P2860
Q27691330-DCE2372C-99A9-43F6-BAC0-D70A2BE6FFC1Q29026697-335C191A-DC72-4B7A-AF61-5D1928DBA1ABQ34515007-4B433DDD-F318-430B-9D06-302014CD29B1Q35688821-0E6882F7-DD45-4DEB-B89C-EDF4D2F91574Q35713265-65525A75-2D42-4D3F-80CE-9C9228070048Q35920773-178D607E-23BF-4DEE-B2C4-904D1F3D41C5Q36015421-AE891070-2760-4CBD-A9D7-6A930377B912Q36210986-0CB3DC26-6E01-4AD6-BB65-4197854367F8Q36821168-0167AC04-D88F-45F7-AB9E-12EB19CA35ABQ37102302-1DE5A1F7-B21B-43EA-B8C9-6E25385FAA9DQ38239661-C4CEB2FE-FC41-40A8-96D8-22235FE8C208Q38262255-6B25DEDF-7528-44CF-899A-272DAB52A23EQ38621231-9FF64AFC-146B-4021-9ED8-3E4AC76BA41DQ38715422-89E18FB1-FC71-4C5E-9C37-1C9886D43A63Q38812269-3BA86E8A-1840-44F3-A75A-869AC8A83840Q38820714-BC7F2ED3-4196-451E-AD56-7A90E69F2009Q38980305-5A66A478-5745-4B72-9680-9EE43BAAB044Q39002838-D5467140-24D5-4227-A8FD-141D6C298D76Q39190801-E515781D-0296-405A-9065-D625649B9743Q40464618-8756876D-9326-49DF-87A8-57B2BAE8DF1DQ41633683-0966A40A-6DB3-4822-9D12-0800ACCF7D6EQ42697252-A6F1178A-933D-4B7A-AA2E-A9991F6CDE0AQ43119856-270E7022-002A-430E-8CFD-450F92AC108FQ47350013-1163F1E0-8797-4213-9B94-A7A70BBE1623Q48184221-47215D38-D5D7-4661-843A-31BC7559F6B1Q52597557-93DDBF24-A398-4E30-9F9C-8A01AF0EEED9Q53140686-E27EBADA-4288-4740-8A71-A051BCF200EFQ56890107-65D82FE8-0D64-4E0C-84A6-ECE42601DB8DQ58740344-C8FD55DB-FAB2-4D4B-B02B-7DBB4EF47B61
P2860
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
The MAPK pathway is a predomin ...... esophageal and gastric cancer.
@en
The MAPK pathway is a predomin ...... esophageal and gastric cancer.
@nl
type
label
The MAPK pathway is a predomin ...... esophageal and gastric cancer.
@en
The MAPK pathway is a predomin ...... esophageal and gastric cancer.
@nl
prefLabel
The MAPK pathway is a predomin ...... esophageal and gastric cancer.
@en
The MAPK pathway is a predomin ...... esophageal and gastric cancer.
@nl
P2093
P2860
P356
P1476
The MAPK pathway is a predomin ...... esophageal and gastric cancer.
@en
P2093
Anja Mueller
Barbara Seliger
Hideki Fujii
Kensuke Shiraishi
Kousaku Mimura
Ley-Fang Kua
Rolf Kiessling
Shinichiro Izawa
Wei-Peng Yong
P2860
P304
P356
10.4049/JIMMUNOL.1301597
P407
P50
P577
2013-11-15T00:00:00Z